Pagetoid reticulosis with CD30 positivity and cytotoxic/suppressor cells

Loading...
Thumbnail Image

Authors

Jacyk, Witold Kamil
Grayson, Wayne
Dinkel, Jurgen Erich
Requena, Luis

Journal Title

Journal ISSN

Volume Title

Publisher

Blackwell

Abstract

Pagetoid reticulosis (PR), also named Woringer-Kolopp disease, is a low-grade primary cutaneous T-cell lymphoma that usually presents as a solitary, slowly enlarging erythematous or hyperkeratotic plaque on the distal areas of the extremities. Histopathologically, it is characterized by a dense, band-like infiltrate of atypical lymphocytes with prominent epidermotropism within a hyperplastic epidermis, and immunophenotypic studies show in most cases, a CD4-positive T-helper phenotype for the neoplastic lymphocytes. We describe an African man with a more than 20-year history of an acral lesion of PR, which was histopathologically characterized by lymphocyte immunophenotype consisting of CD8- and CD30-positive cells. We discuss the differential diagnosis with other primary cutaneous lymphoproliferative disorders showing similar immunophenotype. This case shows that CD30-positive PR should be included as a rare variant within the spectrum of CD30-positive primary cutaneous lymphoproliferative disorders. As in other primary cutaneous CD30-positive lymphoproliferative processes, lesions of CD30-positive PR show an indolent course and a benign biological behavior. Histopathologically, it shows a prominent infiltrate of atypical lymphocytes within a hyperplastic epidermis. Immunophenotypic studies in lesions of PR have led to the recognition of different phenotypes for the large atypical epidermotropic lymphocytes. The CD4-positive T-helper phenotype appears the most common.

Description

Keywords

Pagetoid reticulosis

Sustainable Development Goals

Citation

Jacyk, WK, Grayson, W, Dinkel, JE & Requena, L 2007, ‘Pagetoid reticulosis with CD30 positivity and cytotoxic/suppressor cells’, Journal of Cutaneous Pathology, vol. 34, no. 8, pp. 644–647 [http://www.blackwell-synergy.com/loi/cup]